Testing a new antibody treatment for tick-borne encephalitis in healthy adults
Part of Brain & nervous system, Infections clinical trials.
This study tests a new antibody treatment for tick-borne encephalitis in healthy volunteers. It helps find the right dose and checks if the treatment is safe before it is tried in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must be in generally good health, with no major medical problems.
- You cannot have HIV, active hepatitis B, or active hepatitis C.
- You cannot be taking drugs that suppress your immune system or have a weakened immune system.
- You must agree to use effective birth control for 3 months after the infusion (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for new ways to find the cause of lymphocytic meningitis or meningoencephalitis (inflammation of the brain or its lining) when standard tests don't give an answer. It may help people who have been hospitalized with these conditions and whose spinal fluid tests were unclear or not done.
This study looks at the cost and effectiveness of the tick-borne encephalitis vaccine. It will also track the recovery of patients hospitalized with confirmed tick-borne encephalitis to understand the long-term impact of the disease.
This early-phase trial tests a new antibody-based therapy called SCTB10 in healthy volunteers to see if it's safe and how the body processes it. Participation can help determine the right dose for future patients.
This study looks at blood antibody test results in adults who may have tick-borne encephalitis and also signs of Lyme disease. It may help researchers understand how these infections relate and which lab patterns fit different illnesses.
This study looks at how your body's immune system reacts to a tick bite. It may help doctors understand and prevent tick-borne diseases, which are illnesses spread by ticks, like Lyme disease.
This trial tests a new medicine made from antibodies that target tetanus toxin. It may help protect people from tetanus without needing a vaccine.
Hear when a new The Tick-borne Encephalitis Virus (TBEV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.